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Abstract: The aim of this study was to investigate the role of human herpesvirus-6 (HHV-6)
in autoimmune thyroiditis (AIT) development. We examined the possible involvement of HHV-6
gene expression encoding immunomodulating proteins U12 and U51 in AIT development and their
role in the modulation of chemokine signaling. One hundred patients with autoimmune thyroiditis
following thyroidectomy were enrolled in this study. Nested polymerase chain reaction (nPCR) was
used to detect the HHV-6 sequence in DNA samples. Reverse transcription PCR (RT-PCR) with three
different HHV-6 gene targets (U79/80, U51 and U12) was to detect active infection markers. HHV-6
load was identified using a commercial real-time PCR kit. Immunohistochemistry was performed to
investigate the expression of the HHV-6 antigen and RANTES (Regulated upon Activation, Normal T
Cell Expressed and Secreted) in thyroid gland tissue. Different commercial immunosorbent assay
kits were used for the detection of RANTES, IFNγ, IL-6, and TNFα levels in the AIT patient group
and controls. We detected 98% presence of the HHV-6 genomic sequence in AIT patients’ thyroid
gland tissues. Markers of active HHV-6 infection (HHV-6 U79/80, U12 and/or U51 mRNA) were
predominant in AIT patients’ thyroid tissue samples in comparison with the control group (56% vs.
6%). Evidence from immunofluorescence microscopy showed that HHV-6 can persist in thyrocytes
and can interact with RANTES. Visual confirmation of the intense immunofluorescence signal of
RANTES detected in thyroid tissues could indicate high expression of this chemokine in the thyroid
gland. On the other hand, immunosorbent assays showed very low RANTES levels in AIT patients’
peripheral plasma. These results indicate that RANTES level in AIT patients could be influenced by
HHV-6 activation, which in turn may aid AIT development.
Keywords: autoimmune thyroiditis; HHV-6; RANTES; chemokine receptors
1. Introduction
Autoimmune disease affects the thyroid more than any other organ, and the incidence of
autoimmune thyroiditis (AIT) has dramatically increased over time worldwide [1]. The most common
autoimmune thyroid diseases are Hashimoto thyroiditis (HT) and Graves’ disease. Like other
autoimmune diseases, AIT predominantly affects women, which could be explained by differences
in hormonal background [2]. Autoimmune thyroiditis (AIT) is a big challenge for researchers, as many
of the etiological factors are still unknown.
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Recently, more and more attention has been given to the possible involvement of viruses
in the development of different autoimmune diseases. AIT is no exception—some studies bring
evidence of human herpesvirus-6 (HHV-6) involvement in this disease’s development. A study
mapping the reservoirs of human herpesviruses detected EBV, CMV and HHV-6 in the thyroid gland
tissues of eight autopsies, although without detecting active infection, showing that the thyroid is
potentially susceptible to herpesvirus infection. [3]. A study published by Italian researchers links
HHV-6 to HT [4]. Authors demonstrated that HHV-6 infection could be detected more frequently
in thyroid fine needle aspirates (FNA) from HT patients than in a control group (82% and 10%,
respectively). Furthermore, active HHV-6 transcription is observed only in HT thyrocytes, compared
with the latent infection found in HHV-6-infected thyroid glands used as a control. These researchers
propose a potential mechanism for HHV-6-induced autoimmunity, demonstrating that follicle cells
infected with HHV-6 become susceptible to NK-mediated killing [4]. Our previously published data
also showed an almost 100% incidence rate of the HHV-6 genomic sequence in thyroid gland tissue
samples acquired from AIT patients’ post-surgical materials [5]. We found a significantly higher
presence of the HHV-6 activation marker (HHV-6 U79/80 mRNA) in AIT patients in comparison to
controls (18/44 (41%) vs. 1/17 (6%), respectively; p = 0.0118) [5].
After primary infection, HHV-6 establishes life-long persistency. HHV-6 has the ability to infect
almost every cell in the organism using the CD-46 receptor [6]. Moreover, HHV-6 is known to have
strong immunomodulating properties, which could affect the host over a long period of time and
contribute to several autoimmune disorders, including autoimmune hemolytic anemia/neutropenia [7],
autoimmune acute hepatitis [8], multiple sclerosis [9–11].
Chemokines and their receptors are crucial in both innate and adaptive immune responses. They
ensure the migration of immune cells, their activation and differentiation, which is why many viruses
have evolved the ability to encode viral chemokine receptor homologs. Human chemokine receptors
are G-protein coupled receptors (GPCR). They possess certain structural and chemical characteristics,
like the seven transmembrane domains, which have also been described for viral GPCRs [12,13].
HHV-6 has two genes (U12 and U51) that encode putative homologs of cellular G-protein-coupled
receptors (GPCR) [14,15]. Both share some sequence identity with human CCR 1, 3, 5, 7 and 10 and
can bind several chemokines, among them the chemokine RANTES (Regulated upon Activation,
Normal T Cell Expressed and Secreted) [12]. It has been shown that proteins which are encoded by
HHV-6 U12 and U51 genes could be expressed on the surface of epithelial and some peripheral blood
mononuclear cell populations, which makes them a potential cause for evoking autoimmunity by
making the hosts’ GPCRs into targets for autoreactive T and B lymphocytes [16,17]. Additionally, it has
been shown in vitro that HHV-6 GPCR homologs could interact with cytokines’ signaling pathway by
down-regulating RANTES expression and secretion. RANTES is a β chemokine, which can induce
leukocyte migration upon binding to CCR1, 3 or 5. RANTES is mainly produced by CD8+ T cells,
epithelial cells, fibroblasts and platelets. Virus-specific CD8+ T cells release RANTES, demonstrating
its role in antiviral immune responses. Abnormal levels of RANTES have also been linked to multiple
inflammatory diseases and several autoimmune diseases, but a clear connection between AIT and
RANTES levels has not been established [18,19].
Although multiple studies suggest the association of HHV-6 and AIT, the mechanisms by which
the virus triggers or aggravates autoimmunity have not been clearly elucidated. HHV-6-encoded
chemokine receptor homologs are very poorly studied, so their role in disease development is unclear.
The aim of this study was to investigate the role of HHV-6 by examining the possible involvement of
HHV-6-encoded immunomodulating proteins U12 and U51 in the development of AIT and their role
in chemokine signaling modulation.
Viruses 2020, 12, 689 3 of 12
2. Materials and Methods
2.1. Study Groups
One hundred patients with autoimmune thyroiditis following thyroidectomy were enrolled in this
study, of which 6 were males (6%) and 94 were females (94%), with a median age of 52 (interquartile
range [IQR]: 42–61).
The control group included 30 autopsied subjects (26 women and 4 men; median age 58; IQR: 51–67)
without thyroid pathologies (data on the frequency of HHV-6 infection markers were taken from
previous studies [5] and additional research was carried out to investigate HHV6 U12 and U51 gene
expression) and 35 healthy blood donors (30 women and 5 men; median age 39; IQR: 31–48) to compare
serology results, as the plasma samples from autopsied subjects were not available.
Permission to conduct the research was received from the Ethics Committee of Riga Stradins
University (ethical code Nr 67 and date of approval 25 October 2012) and written consent was obtained
from all the patients and relatives, respectively. Tissue samples were received from the Riga East
Clinical University Hospital.
2.2. Nucleic Acid Isolation, Complementary DNA (cDNA) Synthesis and Quality Determination
DNA from thyroid gland tissues and peripheral blood was extracted using the phenol–chloroform
method. RNA from thyroid gland tissue and peripheral blood mononuclear cells (PBMC) specimens
was extracted using TRI reagent (Life Technologies, Carlsbad, CA, USA), and cDNA was synthesized
using an innuSCRIPT One Step RT-PCR SyGreen Kit (Analytik Jena, Jena, Germany). The integrity
and quality of isolated RNA was tested in denaturing gel electrophoresis using NorthernMax™-Gly
Gel Prep/Running Buffer according to the manufacturer’s protocol (Thermo Fisher Scientific, Waltham,
MA, USA). The quality of genomic DNA and synthesized cDNA was determined by beta (β)-globin
polymerase chain reaction (PCR) with appropriate primers [20].
2.3. Detection of HHV-6 Genomic Sequences and Gene Expression Using Nested PCR (nPCR)
The nPCR technique was used to detect viral genomic sequences in DNA isolated from thyroid
gland tissue and whole blood. PCR amplification of viral DNA was carried out in the presence of 1 µg
of DNA. HHV-6 was detected in accordance with Secchiero et al., 1995 [21], with primers targeting
the HHV-6 major capsid protein (MCP) gene. Positive controls (HHV-6A and HHV-6B genomic DNA;
Advanced Biotechnologies Inc, Columbia, MD, USA) and negative controls (DNA obtained from
healthy HHV-6-negative blood donors and without template DNA) were included in each experiment.
To identify active HHV-6 replication, HHV-6 U79/80 gene expression was detected using nPCR
with cDNA as the template [16] because U79/80-gene-coded proteins have a role in viral DNA
replication [22].
To determine HHV-6 U12 and U51 gene expression, nPCR was performed with cDNA as
the template [16].
2.4. HHV-6 Load Determination Using Quantitative PCR
AIT patients’ and autopsied subjects’ thyroid tissue DNA samples, which were positive
for the presence of the HHV-6 genome sequence, were used for HHV-6 load detection using
the HHV-6 Real-TM Quant (Sacace Biotechnologies, Como, Italy) commercial kit in accordance
with the manufacturer’s instructions (target region: HHV6 polymerase gene; sensitivity: <5 copies of
HHV6 DNA per 105 cells.
2.5. Determination of RANTES (CCL5) Level in Peripheral Blood Plasma by ELISA
Plasma samples acquired from AIT patients’ and blood donors’ peripheral blood were tested for
RANTES level using an ELISA commercial kit (ab100633, Abcam, Cambridge, UK). The ELISA kit
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was used in accordance with the manufacturers’ instructions (sensitivity < 3 pg/mL; detection range
2.74 pg/mL–2000 pg/mL).
2.6. Determination of IFNγ, IL-6, TNFα and RANTES (CCL5) Levels in Peripheral Blood Plasma by
Suspension Multiplex Immuno Assay (SMIA)
Plasma samples acquired from AIT patients’ and blood donors’ peripheral blood were tested for
IFNγ, IL-6, TNFα and RANTES levels using an SMIA commercial kit (HCYTOMAG-60K, Millipore,
Burlington, MA, USA). The SMIA kit was used in accordance with the manufacturers’ instructions
(sensitivity for RANTES: <1.2 pg/mL, for other cytokines <0.9 pg/mL).
2.7. Immunofluorescence Labelling of Formalin-Fixed Paraffin-Embedded (FFPE) Thyroid Tissues
For this study, FFPE thyroid tissue slides (4–5 µm sections) were acquired, the majority of which
were from Grave’s disease and Hashimoto thyroiditis patients.
Slides were loaded into glass slide holders and dewaxed as follows: twice in 100% xylene
(Fisher Scientific, Loughborough, Leicestershire, UK) for 15 min. Afterwards, rehydration was done by
putting slides once into 96% ethanol for 10 min, following a 70% ethanol change for another 10 min.
Finally, the slides were washed three times with PBS (pH = 7.4) for 5 min. A PAP pen for immunostaining
(Z672548-1EA, MilliporeSigma, St. Louis, MO, USA) was used to ring the tissue section.
Cell permeabilization with PBS Triton X100 0.1% for 15 min was necessary, as it improved
immunostaining quality. After washing three times with PBS (pH = 7.4) for 5 min, 200 µL of blocking
solution (PBS plus 1% bovine serum albumin (A3059, Sigma, Germany) and 2% foetal calf serum
(Invitrogen, Carlsbad, CA, USA), filtered through a 0.2 µm filter) was added to the samples and placed
in a moist chamber at room temperature for 1 h. After blocking, slides were washed three times
with PBS.
For immunostaining, mouse monoclonal antibody against HHV-6 gp82/105 antigen (dilution 1:100,
sc-65448, Santa Cruz, Dallas, TX, USA) and goat polyclonal anti-RANTES (CCL5) antibodies (dilution
1:100, ab10590, Abcam, Cambridge, UK) were used as primary antibodies. Rabbit Anti-Mouse IgG
Alexa H&L Fluor® 488 (dilution 1:200, ab150125, Abcam, UK) and Donkey Anti-Goat IgG H&L Alexa
Fluor® 647 (dilution 1:200, ab150131, Abcam, Cambridge, UK) were used as secondary antibodies.
All antibodies were diluted in staining buffer (PBS 1% BSA). Incubation with primary antibodies was
done overnight in a moist chamber at +4 ◦C; after three washes with PBS for 5 min, slides were incubated
with secondary antibodies in a moist chamber at room temperature for 1 h. After another three washes
with PBS, slides were incubated with PBS containing 1.43 µM 4′,6-diamidino-2-phenylindole (DAPI;
D21490, Invitrogen, Carlsbad, CA, USA) for five minutes at room temperature. BrightMount/Plus
Aqueous Mounting Medium (Anti-fading) for Fluorescent Staining (ab103748, Abcam, Cambridge,
UK) was added to the slides and sealed with a cover glass and nail varnish all around the perimeter.
For immunofluorescence sections, digital images were captured using a Nikon EclipseTi-E confocal
scanning microscope.
3. Results
3.1. Detection of HHV-6 Virus Genomic Sequence and Its mRNAs in AIT Patients and Control Group
Autopsy Specimens
The HHV-6 genomic sequence was found in 98 (98%) AIT patients’ thyroid gland tissue DNA
samples and in 23 (77%) autopsy samples (p = 0.0005) (data on the control group taken from previous
publication by Sultanova et al., 2017 [5]). The HHV-6 genomic sequence was found in only 16 out of 98
(16%) AIT patients’ peripheral blood DNA samples, showing that the infection occurs predominantly
in the thyroid gland, not in the circulating cells.
The overall presence of different HHV-6 mRNAs (U79/80, U12 and/or U51) was found to be
significantly higher (p = 0.005) in the AIT patient group than in the control group (56% against 6%,
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respectively). The presence of HHV-6 chemokine receptor mRNAs (U12 and/or U51 mRNAs) was
found only in AIT patients’ thyroid gland tissue samples (38/98; 39%).
As shown in Figure 1:
• 17/98 (17%) AIT patients’ thyroid tissue samples and 8/16 (50%) PBMC samples were positive for
HHV-6 U79/80 mRNA.
• 6/98 (6%) AIT patients’ thyroid tissue samples were positive for HHV-6 U12 mRNA, while none
of the PBMC samples were HHV-6 U12 mRNA-positive and 3/98 (3%) thyroid tissue samples of
AIT patients and 4/16 (25%) PBMC samples were positive for HHV-6 U51 mRNA.
• U79/80 + U12 mRNA was found in 3/98 (3%) AIT patients’ thyroid tissue samples, while none
of the PBMC samples were HHV-6 U79/80 + U12 mRNA-positive; U79/80 + U51 mRNAs were
present in 3/98 (3%) AIT patients’ thyroid tissue samples and in none of the PBMC samples.
• U79/80 + U12 + U51 mRNAs were present in 19/98 (20%) AIT patients’ thyroid tissue samples and
in none of the PBMC samples.
• U12 + U51 mRNAs were found only in 4/98 (4%) AIT patients’ thyroid tissue samples.
• The presence of HHV-6 U79/80 mRNA was only detected in 1/17 autopsy samples (data from
previous study [5]), and no HHV-6 U12 or U51 mRNAs were found in this study.
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Figure 1. Distribution of HHV-6 U79/80 (encoding proteins involved in viral replication), U12 and U51
mRNAs (late and early genes, respectively, encoding viral homologs of cellular G-protein-coupled
receptors) in AIT patients’ thyroid gland tissue samples. Results from nPCR investigations of viral
gene expression using cDNA as a template.
Presence of any HHV-6 transcripts (U79/80; U12 and U51 mRNAs) in individuals was considered
as the presence of an active viral infection, while absence was considered as the presence of a latent
infection, as these genes are expressed during productive viral infection.
3.2. HHV-6 Load in Thyroid Tissue Samples
Median HHV-6 load was found to be higher in AIT patients’ thyroid gland tissue samples with
markers of active HHV-6 infection (582.7 [IQR: 168.4–2191.0] viral copies/106 cells) in comparison
to AIT patients’ thyroid gland tissue samples without markers of active HHV-6 infection
(361.0 [IQR: 110.0–1029.0] viral copies/106 cells); however, a Mann–Whitney test showed no significance
(p = 0.3851; Figure 2).
Comparison of HHV-6 loads found in patients’ thyroid gland samples with HHV-6 U12 and/or
U51 mRNA expression and viral load in thyroid tissue samples without HHV-6 U12 and/or U51 mRNA
expression showed a significantly higher median value in the former (1011.0 [IQR: 377.7–3076.0] vs.
425.6 [IQR: 64.8–2385.0] viral copies/106 cells; p = 0.0494; Figure 2).
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Figure 2. Median HHV-6 load (error bars indicating IQR) detected in AIT patients’ thyroid gland
Table 6. Load was indicated as log HHV-6 copies per 106 cells. HHV-6 U12 and U51 encode viral
homologs of cellul r G-protein-coupled receptors.
Samples where at least one of U12, U51 or U79/80 mRNA was detected were considered to have
active HHV-6 infection, whereas, when no viral mRNAs were detected, samples were considered to
harbor latent HHV-6 nfection. Information about HHV-6 load and g ne expres ion was acquired
using qPCR and nPCR methodology, respectively.
3.3. RANTES Level in Plasma of AIT Patient and Blood Donor Groups Detected with ELISA and SMIA
RANTES plasma levels were determined by ELISA in patients with AIT and blood donors. AIT
patients had statistically lower RANTES levels (median 9.267 [IQR: 3.489–16.93] pg/mL) than blood
donors (median 56.6 [IQR: 30.71–101.5] pg/mL). The same samples were tested additionally with
a commercial SMIA kit. RANTES plasma levels determined by SMIA in patients with AIT and blood
donors also showed that IT patients had statistically lower RANTES levels (median 150.3 [IQR:
71.6–418.2] pg/mL) than blood donors (median 1359.0 [IQR: 844.2–2596.0] pg/mL; Figure 3) but with
better detection range and higher sensitivity.
AIT patients with active infection, in which U12 and U51 gene expression was detected, showed
much lower RANTES levels than patients with latent viral infection (median 45.58 [IQR: 3.2–158.2] vs.
108.2 [IQR: 28.0–306.9] pg/mL); however, significance was not established (p = 0.0607).
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Figure 3. RANTES, IFNγ, IL-6, and TNFα median levels (error bars indicating IQR) in the plasma of
AIT patient and blood donor groups. Chemokine (RANTES) and pro-inflammatory cytokine (IFNγ,
IL-6 and TNFα) levels from SMIA investigations are expressed as pg/mL. IFNγ, IL-6 and TNFα were
chosen as they participate in RANTES induction.
3.4. IFNγ, IL-6 and TNFα Levels in Plasma of AIT Patient and Blood Donor Groups
IFNγ and TNFα levels were found to be significantly (p = 0.035 and p = 0.007) elevated in AIT
patients’ plasma samples (median 2.7 [IQR: 2.1–3.0] and 14.0 [IQR: 10.1–16.9] pg/mL, respectively)
in comparison to control group samples (median 2.2 [IQR: 1.7–2.7] and 10.6 [IQR: 9.5–13.5] pg/mL;
Figure 3). Although some AIT patients had very high IL-6 levels, the median value was not found to be
significantly different fro the control group’s median (median 9.1 [IQR: 1.1–76.2] vs. 7.3 [IQR: 2.6–21.5]
pg/mL; Figure 3). The absence of statistical significance could be explained by the extremely low IL-6
level in individuals, as detectable levels were found only in 10 AIT patients’ and in 8 control groups’
plasma samples (assay sensitivity is 0.9 pg/mL; HCYTOMAG-60K, Millipore, USA).
3.5. Detection of HHV-6 Antigen and RANTES by Immunofluorescence Microscopy
Immunostaining with antibodies against HHV-6 gp82/105 antigen and goat polyclonal
anti-RANTES (CCL5) ant bodies showed a clear presence of viral i fection in thyrocytes (thyroid
epithelial cells forming follicl ) (Figure 4; Row A—Al xa488 and Merged (arrows)). The histological
struc ure of the gland was expressed in a single layer of well-distinguished round nuclei of thyroid
follicular cells lining the colloid matrix. In ome areas, rare, smaller lymphocytic nuclei were seen,
integrated betwee the cells f the epi helial cell laye forming follicles and separa ed by interstitium.
Morphological inv stigation all samples revea ed the localized presence of HHV-6 ant gen, often
accom anied by RANTES expression). Against th background of the blue fluorescence-marked
(DAPI-stai ed) nuclei of the pithelial cells encircling the coll id pools of the fol icular cluster nd
the cells within the onnec ive intra- obular tissue, a weak fluorescence signal of HHV-6 antibody
tagging was observed in separate cells. A mainly zonal distribution f HHV-6 v ral particles in the apical
cell cytoplasm was observed (Figur 4; Row A—A exa488 and Merged (arrows)). In some areas, a red
Viruses 2020, 12, 689 8 of 12
fluorescence signal was found indicating the presence of RANTES, mainly observed in close connection
to the epitopes of viral expression marked with Alexa488 (Figure 4; Row B—Alexa647 and Merged
(arrows)). Another important point is that the simultaneous presence of HHV-6 antigen and RANTES
was observed at the site of the damaged cells’ structure (Figure 4; Row B—Merged and TD + Merged).
Meanwhile, in undamaged cells, only the viral antigen was detected (Figure 4; Row A—Merged and
TD + Merged). This could indicate the important role of RANTES in the destruction of thyroid cells
and possible involvement of this chemokine in interaction with HHV-6.
Figure 4. Fluorescent microscopy of thyroid gland tissue. Dyes: DAPI—nucleus; Alexa488—HHV-6
gp82/105 (closed tip arrows (bold)); Alexa647—RANTES (opened tip arrows (sharp)); TD—transmitted
light. Channels Alexa488 and Alexa647 are shown in greyscale for better contrast. Row A—part of
a thyroid lobule of a patient with Grave’s disease; Row B—limitrophe zone of two separate thyroid
follicles of a patient with Grave’s disease; Row C—control patient’s (with adenoma) thyroid lobule;
Row D—staining control (secondary antibodies and DAPI only).
No presence of the HHV-6 antigen or RANTES was observed in the control patient (thyroid gland
adenoma) sample (Figure 4; Row C—Alexa488 and Alexa647). Additionally, the staining control
showed the absence of secondary antibodies’ unspecific binding (Figure 4; Row C—Alexa488 and
Alexa647).
4. Discussion
The etiopathogenesis of AIT is not yet fully understood as the disease is multifactorial. Nowadays,
there is more concern about the involvement of viral infections as important factors in AIT development.
In this study, we have shown evidence of the importance of HHV-6 in AIT development. We detected
almost 100% presence of the HHV-6 genomic sequence in AIT patients’ thyroid gland tissues.
This is a significant difference in comparison with HHV-6 distribution in the control group (98%
vs. 77%; p = 0.0058) published in our previous study [5]. Markers of active HHV-6 infection (HHV-6
U79/80, U12 and/or U51 mRNA) were predominantly present in AIT patients’ thyroid tissue samples
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in comparison to the control group (56% vs. 6%). These results indicate that HHV-6 cannot be ignored
as a potential autoimmunity trigger factor in AIT development, as its presence and gene expression
was predominantly found in AIT patients.
Infectious agents like HHV-6 can initiate autoimmune processes in the thyroid gland by a variety
of mechanisms, such as modifying the antigen itself, mimicking the host’s molecules, and initiating
polyclonal T-cell activation [23]. HHV-6 encodes two viral chemokine receptors (GPCRs), U12 and
U51, which are structurally similar to cellular G-protein-coupled receptors [15], but the role of these
genes is not well understood. HHV-6 U12 and U51 are functionally similar to the much-better-studied
CMV protein US28 (pUS28), which enhances the course of CMV infection by inhibition of chemokines
through interactions the with host’s beta-chemokine receptors [24]. Proteins encoded by the HHV-6 U12
and U51 genes can be expressed on the surface of epithelial and some peripheral blood mononuclear
cell populations, making them a potential cause for the initiation of the autoimmunity process, where
host GPCRs could be targeted by auto-reactive T and B lymphocytes. In-vitro HHV-6 GPCR may also
interact with the cytokine signaling pathway, leading to down-regulation of RANTES [14,16]. Both of
these factors make the U12 and U51 proteins ideally suited for studying the involvement of HHV-6
in the development of autoimmune thyroiditis.
In this study, 39% of AIT patients had HHV-6 U12 and/or U51 mRNA in thyroid tissue samples.
This means that more than one third of AIT patients’ thyroid tissue expressed viral chemokine
receptors and none of the control group’s thyroid samples contained any of these mRNAs. Additional
experiments are needed to obtain evidence for the presence of HHV-6 proteins on thyrocytes by methods
such as Western blotting or immunofluorescence. However, specific antibodies that are not currently
available on the market are needed to obtain clearer evidence. The lack of these antibodies could be
explained by the difficulty in obtaining antigens for immunization because of the transmembrane
nature of these proteins and by the difficulty in purifying them. This problem could be solved by
the use of many different synthetic peptides (made from HHV-6 amino acid sequences).
For the next step, we determined RANTES levels, as HHV-6 U12 and U51 can interfere with this
chemokine, and the chemokine plays an important role in the selective recruitment of circulating T-cells.
Initially, we used a commercial ELISA kit (ab100633, Abcam, UK) and received results that showed
statistically lower RANTES levels in the AIT patients’ group (median 9.267, IQR: 3.489–16.93 pg/mL)
compared to blood donors (median 56.6, IQR: 30.71–101.5 pg/mL). However, we soon switched to
a different immunological assay—the Suspension Multiplex Immuno Assay (SMIA) and Luminex
200 system. SMIA has two major advantages in comparison to ELISA: (1) since the reaction runs
in suspension, it has a higher sensitivity; (2) MagPlex—magnetic beads with 100 different specific
fluorescent regions—allow simultaneous detection of up to 100 different analytes in a sample. The SMIA
kit showed similar results to ELISA but with a higher range for a significantly lower level of RANTES
in AIT patients’ plasma samples (median 150.3 [IQR: 71.6–418.2] pg/mL) as opposed to blood donors
(median 1359.0 [IQR: 844.2–2596.0] pg/mL). This range is more realistic in comparison with other
published results on RANTES [25,26]. At the moment, it is not clear how low RANTES production
is involved in AIT development; however, in studies of other autoimmune diseases—autoimmune
Addison disease and rheumatoid arthritis—RANTES plasma level was significantly elevated [27,28].
One of the studies showed that AIT patients could be more susceptible to lower RANTES levels as
they had a significantly lower frequency of the RANTES 403A genotype, which is involved in higher
production of RANTES in comparison to controls [29].
Findings from immunofluorescence microscopy show that HHV-6 can persist in thyrocytes
and can interact with RANTES. Visual confirmation of an intense immunofluorescence signal of
RANTES detected in thyroid tissues could indicate higher expression of this chemokine in the thyroid
gland—however, quantitative RANTES gene expression comparison in peripheral blood and thyroid
tissue should be performed in order to obtain stronger evidence.
In addition, were reported data suggesting a potential role of follicular cells, through the production
of the chemokines Ip-10, Mig and RANTES, in activating specific lymphocyte subsets in AIT patients [30].
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Therefore, significant differences in the expression of RANTES between thyroid gland follicular cells
and peripheral blood can create opportunistic circumstances for lymphocytes’ migration into the site
of higher expression of this chemokine, i.e., the thyroid gland, thereby provoking autoimmunity
processes. This means that any infection in the thyroid gland, in this case HHV-6 infection, could
possibly act as a trigger factor for the entire cascade leading to AIT development.
Moreover, in this study, we found that levels of INF-γ and TNF-α, pro-inflammatory cytokines
which are implicated in RANTES induction, were significantly elevated in AIT patients in comparison
to controls. These pro-inflammatory cytokines stimulate endothelial cells to express the CC chemokine
RANTES, which leads to selective recruitment of circulating cells [31]. Elevated INF-γ and TNF-α
levels and downregulated CC chemokine (RANTES levels are similar to classic β-herpesvirus infection
and its mechanism of evading the immune response. Induction of INF-γ and TNF-α occurs before viral
gene expression, suggesting that the response might be a cellular response to announce foreign invasion
and to stimulate an inflammatory response, but, after expression of viral genes begins, down-regulation
of RANTES and other CC chemokines takes place [31–34]. Although statistical significance was not
found, we observed lower RANTES levels in AIT patients in whom U12 and U51 gene expression was
detected (median 45.58 [IQR: 3.2–158.2] vs. 108.2 [IQR: 28.0–306.9] pg.
Furthermore, the highest median viral load was detected in AIT patients with lowest RANTES
level and with HHV-6 U12/U51 mRNA. These results indicate that RANTES level in AIT patients could
be influenced by HHV-6 activation, which in turn may aid AIT development. In conclusion, to make
strong statements, a deeper investigation should be done, although, from our results, it is clear that
AIT patients have a disturbance in the RANTES signaling pathway, and that HHV-6 could influence it.
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